At a Glance
AI-generated6-K
BrainsWay Ltd. completed an additional $6 million milestone-based convertible loan to Neurolief Ltd., triggered by FDA Premarket Approval of Neurolief's Proliv™ Rx system for treatment-resistant major depressive disorder, bringing total investment to $11 million. The strategic agreement includes potential further $5 million equity tranche and a call option to acquire Neurolief.—
Market Cap
—
Revenue
—
Net Income
Employees120
Fundamentals
How The Business Makes Money
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Industry Medical - Devices
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001505065
ISINIL0011007189
Phone972 2 582 4030
AddressBynet Building, Jerusalem, 9777518, IL
SEC EDGAR